AST SpaceMobile's shares plunged following the BlueBird 7 satellite's incorrect deployment during a Blue Origin New Glenn launch, highlighting execution risks. Q4 2025 revenue surged 2,731% year-over-year, driven by government and mobile network operator (MNO) contracts, boosting earlier sentiment.
Post-IPO volatility persists, with shares rebounding year-to-date amid aerospace sector interest. Expanded collaboration with Blackstar Orbital advances reusable hypersonic systems testing.
SPCE stock surged +21% over the past 30 days, driven by resumed ticket sales at elevated prices and progress on next-generation spacecraft testing. Over the past quarter, shares declined -5%, reflecting pressure from weak fourth-quarter earnings and persistent cash burn concerns.
Voyager Technologies secured a NASA contract for its seventh private astronaut mission to the ISS, driving an 8.8% stock surge in recent sessions. Record $266 million backlog and raised 2026 revenue guidance to $225-255 million highlight strong defense segment growth.
MDA Space Ltd. reported record Q4 2025 revenue growth of 44%, boosting investor confidence.
LUNR stock surged +55% over the past 30 days, driven primarily by a major NASA contract award and heightened space sector enthusiasm. Over the past quarter, shares rose +41%, supported by strong 2026 revenue guidance from recent earnings and expanding NASA backlog.
Redwire secured over $20 million in follow-on orders from the U. S.
SIDU stock surged +132% over the past 30 days, driven by a major expansion with Lonestar Data Holdings for orbital data storage and a $58.5 million capital raise. The stock experienced high volatility with sharp gains in early April, peaking near $6 before a slight pullback.
Rocket Lab USA's shares have shown strong gains in recent weeks, driven by a $190 million Department of Defense (DoD) contract for hypersonic tests. The company maintains a robust $1.85 billion backlog, signaling sustained revenue visibility.
FBYD stock surged +88% over the past 30 days, driven primarily by strong fourth-quarter 2025 earnings highlighting revenue growth in the Falcon's Creative Group segment. Over the past quarter, shares climbed +124%, reflecting a broader recovery amid small-cap market momentum and operational improvements.
RLAY stock surged +69% over the past 30 days, propelled by positive clinical data updates on its lead candidate zovegalisib. Over the past quarter, shares climbed +122%, supported by an earnings beat and advancing pipeline milestones.
CODI stock surged +72% over the last 30 days, primarily driven by the announcement of the $292.5 million sale of its Sterno food service business to reduce debt. Over the past quarter, shares climbed +88%, reflecting recovery from earlier lows amid improved subsidiary performance and strategic divestitures.
MapLight Therapeutics (MPLT) stock price rose +71% over the last 30 days amid strong analyst buy ratings and anticipation for Phase 2 clinical trial readouts. Over the past quarter, shares climbed +76%, supported by a robust cash position from its recent initial public offering (IPO) and positive regulatory designations.
HTZ stock surged +88% over the past 30 days, rising from $3.95 to $7.43, driven by strong rental demand and rising used vehicle values. Over the past quarter, shares gained +38%, recovering from a mid-period low amid positive momentum from Q4 earnings.
AMC stock surged +82% over the past 30 days, fueled by record Easter box office results and blockbuster hits like the Super Mario Bros. film.
NAK stock surged +85% over the past 30 days, driven primarily by optimism surrounding legal developments in the Pebble Project court case. Over the past quarter, shares rose +2%, reflecting volatile trading amid ongoing litigation and annual filings highlighting going-concern risks.
PAYS stock price surged +95% over the last 30 days, primarily fueled by robust fourth-quarter earnings highlighting 40% revenue growth. Over the past quarter, the stock rose +45%, supported by sustained expansion in patient affordability solutions.
ANL stock surged +116% over the past 30 days, driven primarily by a $150 million private placement equity financing announced mid-April. Over the past quarter, shares rocketed +765%, fueled by clinical trial advancements and multiple large financings amid positive analyst sentiment.
Newmont Corporation (NEM) stock rose approximately +19% over the past 30 days, driven primarily by a sharp recovery in gold prices to record highs near $5,000 per ounce. Over the past quarter, shares gained +2%, reflecting sustained gold market strength offset by rising operational costs and production disruptions.
AEM shares surged +23% over the past 30 days, propelled by a rally in gold prices amid geopolitical tensions and safe-haven demand. Over the past quarter, AEM gained +5%, reflecting volatility with a mid-period dip followed by recovery on strong operational results and higher gold realizations.